This brand name is authorized in Austria, Australia, Canada, Cyprus, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Japan, Lithuania, Netherlands, New Zealand, Poland, Romania, Singapore, Tunisia, Turkey, United Kingdom, United States, South Africa
The drug EYLEA contains one active pharmaceutical ingredient (API):
1
Aflibercept
UNII 15C2VL427D - AFLIBERCEPT
|
Aflibercept, also known as VEGF TRAP in the scientific literature, is a recombinant fusion protein consisting of VEGF-binding portions from the extracellular domains of human VEGF receptors 1 and 2 fused to the Fc portion of the human IgG1. Aflibercept blocks the activation of VEGF receptors and the proliferation of endothelial cells, thereby inhibiting the growth of new vessels that supply tumours with oxygen and nutrients. |
Below package inserts are available for further reading:
Title | Information Source | Document Type | |
---|---|---|---|
EYLEA 114.3 mg/ml Solution for injection | European Medicines Agency (EU) | MPI, EU: SmPC | |
EYLEA 40 mg/mL Solution for injection in pre-filled syringe | European Medicines Agency (EU) | MPI, EU: SmPC | |
EYLEA 40 mg/ml Solution for injection | European Medicines Agency (EU) | MPI, EU: SmPC |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
ATC code | Group title | Classification |
---|---|---|
S01LA05 | Aflibercept | S Sensory organs → S01 Ophthalmologicals → S01L Ocular vascular disorder agents → S01LA Antineovascularisation agents |
This drug has been assigned below unique identifiers within the countries it is being marketed:
Country | Identification scheme | Identifier(s) |
---|---|---|
Country: AU | Pharmaceutical Benefits Scheme | Identifier(s): 10505X, 11991D, 12131L, 12132M, 12141B, 12152N, 12153P, 2168D |
Country: CA | Health Products and Food Branch | Identifier(s): 02415992, 02505355 |
Country: EE | Ravimiamet | Identifier(s): 1601457, 1601468 |
Country: ES | Centro de información online de medicamentos de la AEMPS | Identifier(s): 112797001, 112797002 |
Country: FI | Lääkealan turvallisuus- ja kehittämiskeskus | Identifier(s): 145450, 532599 |
Country: FR | Base de données publique des médicaments | Identifier(s): 68795701, 69613703 |
Country: GB | Medicines & Healthcare Products Regulatory Agency | Identifier(s): 216745, 381939 |
Country: HK | Department of Health Drug Office | Identifier(s): 61971 |
Country: IL | מִשְׂרַד הַבְּרִיאוּת | Identifier(s): 7384, 9081 |
Country: JP | 医薬品医療機器総合機構 | Identifier(s): 1319405A1027, 1319405G1020 |
Country: LT | Valstybinė vaistų kontrolės tarnyba | Identifier(s): 1068441, 1093378 |
Country: NL | Z-Index G-Standaard, PRK | Identifier(s): 103756 |
Country: NZ | Medicines and Medical Devices Safety Authority | Identifier(s): 15565 |
Country: PL | Rejestru Produktów Leczniczych | Identifier(s): 100291098 |
Country: RO | Agenția Națională a Medicamentului și a Dispozitivelor Medicale | Identifier(s): W63881001, W68189001 |
Country: SG | Health Sciences Authority | Identifier(s): 14345P, 14380P |
Country: TN | Direction de la Pharmacie et du Médicament | Identifier(s): 12853081H |
Country: TR | İlaç ve Tıbbi Cihaz Kurumu | Identifier(s): 8699546770052, 8699546959358 |
Country: US | FDA, National Drug Code | Identifier(s): 61755-005 |
Country: ZA | Health Products Regulatory Authority | Identifier(s): 46/15.4/0841 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.